Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 2.02
RGLS's Cash-to-Debt is ranked lower than
67% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. RGLS: 2.02 )
Ranked among companies with meaningful Cash-to-Debt only.
RGLS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.76  Med: 8.55 Max: No Debt
Current: 2.02
Equity-to-Asset 0.32
RGLS's Equity-to-Asset is ranked lower than
72% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RGLS: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
RGLS' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.26  Med: 0.7 Max: 0.89
Current: 0.32
-1.26
0.89
Piotroski F-Score: 1
Altman Z-Score: -9.37
Beneish M-Score: 220.15
WACC vs ROIC
13.53%
-18451.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -30986.43
RGLS's Operating Margin % is ranked lower than
92% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. RGLS: -30986.43 )
Ranked among companies with meaningful Operating Margin % only.
RGLS' s Operating Margin % Range Over the Past 10 Years
Min: -30986.43  Med: -180.19 Max: -51.76
Current: -30986.43
-30986.43
-51.76
Net Margin % -31460.47
RGLS's Net Margin % is ranked lower than
92% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. RGLS: -31460.47 )
Ranked among companies with meaningful Net Margin % only.
RGLS' s Net Margin % Range Over the Past 10 Years
Min: -31460.47  Med: -180.9 Max: -55.13
Current: -31460.47
-31460.47
-55.13
ROE % -147.08
RGLS's ROE % is ranked lower than
81% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. RGLS: -147.08 )
Ranked among companies with meaningful ROE % only.
RGLS' s ROE % Range Over the Past 10 Years
Min: -169.02  Med: -50.28 Max: -24
Current: -147.08
-169.02
-24
ROA % -83.01
RGLS's ROA % is ranked lower than
77% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. RGLS: -83.01 )
Ranked among companies with meaningful ROA % only.
RGLS' s ROA % Range Over the Past 10 Years
Min: -83.01  Med: -35.57 Max: -16.48
Current: -83.01
-83.01
-16.48
ROC (Joel Greenblatt) % -679.13
RGLS's ROC (Joel Greenblatt) % is ranked lower than
56% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. RGLS: -679.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RGLS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1544.17  Med: -592.79 Max: -450.68
Current: -679.13
-1544.17
-450.68
3-Year Revenue Growth Rate -64.40
RGLS's 3-Year Revenue Growth Rate is ranked lower than
88% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. RGLS: -64.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RGLS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -77 Max: -36.1
Current: -64.4
3-Year EBITDA Growth Rate 49.00
RGLS's 3-Year EBITDA Growth Rate is ranked higher than
88% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. RGLS: 49.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RGLS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -46.25 Max: 49
Current: 49
0
49
3-Year EPS without NRI Growth Rate 46.80
RGLS's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. RGLS: 46.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RGLS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -47.7 Max: 46.8
Current: 46.8
0
46.8
GuruFocus has detected 5 Warning Signs with Regulus Therapeutics Inc $RGLS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RGLS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

RGLS Guru Trades in Q3 2016

Jim Simons 645,000 sh (New)
» More
Q4 2016

RGLS Guru Trades in Q4 2016

Paul Tudor Jones 46,688 sh (New)
Jim Simons 321,200 sh (-50.20%)
» More
Q1 2017

RGLS Guru Trades in Q1 2017

Paul Tudor Jones 108,061 sh (+131.45%)
Jim Simons 118,341 sh (-63.16%)
» More
Q2 2017

RGLS Guru Trades in Q2 2017

Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with RGLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:TSXV:COB.U, NAS:AGTC, NAS:CFRX, NAS:GEMP, AMEX:PFNX, NAS:ZYNE, AMEX:SYN, NAS:GTXI, NAS:ONSIU, NAS:BCLI, NAS:CYTR, NAS:ZFGN, NAS:ARQL, NAS:MRNS, AMEX:NBY, NAS:OPHT, OTCPK:EGRN, OTCPK:MRMD, OTCPK:IPIX, LSE:MTFB » details
Traded in other countries:7RG.Germany,
Headquarter Location:USA
Regulus Therapeutics Inc is a biotechnology company that focuses on the development of microRNA therapies. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome.

Regulus Therapeutics is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Ratios

vs
industry
vs
history
PB Ratio 2.45
RGLS's PB Ratio is ranked higher than
86% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. RGLS: 2.45 )
Ranked among companies with meaningful PB Ratio only.
RGLS' s PB Ratio Range Over the Past 10 Years
Min: 1.04  Med: 3.46 Max: 12.95
Current: 2.45
1.04
12.95
PS Ratio 230.00
RGLS's PS Ratio is ranked lower than
81% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. RGLS: 230.00 )
Ranked among companies with meaningful PS Ratio only.
RGLS' s PS Ratio Range Over the Past 10 Years
Min: 0.11  Med: 20.99 Max: 400
Current: 230
0.11
400
EV-to-EBIT -0.94
RGLS's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. RGLS: -0.94 )
Ranked among companies with meaningful EV-to-EBIT only.
RGLS' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.9  Med: -6.2 Max: -0.1
Current: -0.94
-24.9
-0.1
EV-to-EBITDA -0.98
RGLS's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. RGLS: -0.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
RGLS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.9  Med: -6.5 Max: -0.1
Current: -0.98
-25.9
-0.1
Current Ratio 4.49
RGLS's Current Ratio is ranked higher than
65% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. RGLS: 4.49 )
Ranked among companies with meaningful Current Ratio only.
RGLS' s Current Ratio Range Over the Past 10 Years
Min: 1.64  Med: 8.03 Max: 12.36
Current: 4.49
1.64
12.36
Quick Ratio 3.94
RGLS's Quick Ratio is ranked higher than
64% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. RGLS: 3.94 )
Ranked among companies with meaningful Quick Ratio only.
RGLS' s Quick Ratio Range Over the Past 10 Years
Min: 1.64  Med: 8.03 Max: 12.36
Current: 3.94
1.64
12.36
Days Sales Outstanding 976.16
RGLS's Days Sales Outstanding is ranked lower than
91% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. RGLS: 976.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.47  Med: 94.62 Max: 976.16
Current: 976.16
1.47
976.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.20
RGLS's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. RGLS: -8.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RGLS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -719.3  Med: -10.95 Max: 0
Current: -8.2
-719.3
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 6.13
RGLS's Price-to-Net-Current-Asset-Value is ranked higher than
87% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. RGLS: 6.13 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RGLS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.04  Med: 4.35 Max: 8.11
Current: 6.13
2.04
8.11
Price-to-Tangible-Book 2.56
RGLS's Price-to-Tangible-Book is ranked higher than
89% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. RGLS: 2.56 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RGLS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.74  Med: 3.73 Max: 7.36
Current: 2.56
1.74
7.36
Price-to-Median-PS-Value 11.50
RGLS's Price-to-Median-PS-Value is ranked lower than
92% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. RGLS: 11.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RGLS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 1.03 Max: 12.25
Current: 11.5
0.01
12.25
Earnings Yield (Greenblatt) % -105.51
RGLS's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. RGLS: -105.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RGLS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4226.3  Med: -16.25 Max: -4
Current: -105.51
-4226.3
-4

More Statistics

Revenue (TTM) (Mil) $0.26
EPS (TTM) $ -1.54
Beta1.92
Short Percentage of Float8.21%
52-Week Range $0.79 - 3.65
Shares Outstanding (Mil)103.79

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 0 0 0
EPS ($) -1.22 -1.05 -1.41
EPS without NRI ($) -1.22 -1.05 -1.41
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RGLS

Headlines

Articles On GuruFocus.com
Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference Aug 08 2017 
Regulus Reports Second Quarter 2017 Financial Results and Recent Events Aug 01 2017 
Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters Jul 25 2017 
Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017 Jul 25 2017 
Regulus Announces Pricing of Public Offering of Common Stock Jul 19 2017 
Regulus Announces Commencement of Public Offering of Common Stock Jul 19 2017 
Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer Jun 13 2017 
Regulus Announces Pipeline Updates and Advancements Jun 12 2017 
Pascale Witz Joins Regulus Board of Directors Jun 01 2017 
Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring May 04 2017 

More From Other Websites
Edited Transcript of RGLS earnings conference call or presentation 1-Aug-17 9:00pm GMT Aug 13 2017
Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference Aug 08 2017
Regulus reports 2Q loss Aug 01 2017
Regulus Reports Second Quarter 2017 Financial Results and Recent Events Aug 01 2017
Investor Network: Regulus Therapeutics Inc. to Host Earnings Call Aug 01 2017
Regulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of Shares Jul 25 2017
Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of... Jul 25 2017
Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017 Jul 25 2017
Regulus Announces Pricing of Public Offering of Common Stock Jul 19 2017
Regulus Announces Commencement of Public Offering of Common Stock Jul 19 2017
Chardan Capital Slashed Price Target on Regulus Therapeutics Inc (RGLS) Following Program... Jun 13 2017
Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip Jun 13 2017
Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer Jun 13 2017
Regulus Announces Pipeline Updates and Advancements Jun 12 2017
Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics Jun 08 2017
Pascale Witz Joins Regulus Board of Directors Jun 01 2017
Edited Transcript of RGLS earnings conference call or presentation 4-May-17 9:00pm GMT May 17 2017
Q1 Losses Couldn't Drag Regulus or Corvus Pharmaceuticals Down May 08 2017
Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring May 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}